Research Synopsis: Structural biology, drug discovery, clinical medicine and oncology
Stephen Burley is an expert in structural biology, proteomics, bioinformatics, structure/fragment based drug discovery, and clinical medicine/oncology. Burley currently serves as a Distinguished Professor in the Department of Chemistry and Chemical Biology, Director of the Center for Integrative Proteomics Research, and Director of the RCSB Protein Data Bank at Rutgers, The State University of New Jersey. He is also the Founding Director of the Institute for Quantitative Biomedicine at Rutgers and a Member of the Rutgers Cancer Institute of New Jersey.
From 2008 to 2012, Burley was a Distinguished Lilly Research Scholar in Lilly Research Laboratories. Prior to joining Lilly, Burley served as the Chief Scientific Officer and Senior Vice President of SGX Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Lilly in 2008. Until 2002, Burley was the Richard M. and Isabel P. Furlaud Professor at The Rockefeller University, and an Investigator in the Howard Hughes Medical Institute.
He has authored/coauthored more than 250 scholarly scientific articles. He is a Fellow of the Royal Society of Canada and of the New York Academy of Sciences. Burley received an M.D. degree from Harvard Medical School in the joint Harvard-MIT Health Sciences and Technology program and, as a Rhodes Scholar, received a D.Phil. in Molecular Biophysics (structural biology) from Oxford University. He trained in internal medicine at the Brigham and Women's Hospital, and did post-doctoral work with Gregory A. Petsko at the Massachusetts Institute of Technology and William N. Lipscomb at Harvard University. With William J. Rutter and others at the University of California, San Francisco and Rockefeller, Burley co-founded Prospect Genomics, Inc., which was acquired by SGX in 2001.